Frazier-Backed Mavupharma Scores $20M to Fund STING Program
The Series A funding will be used primarily to advance Mavu's lead drug candidates into the clinic. Source: BioSpace
Alkermes Allegedly Fired 3 Female Employees Who Raised Concerns of Bias
After being criticized earlier this month by U.S. Sen. Kamala Harris, three separate sexual harassment lawsuits have been reported. Source: BioSpace
Boston Scientific Loses $3B on Latest Lotus Valve Delay
A delay in returning its Lotus Edge Aortic Valve System to the market has cost Boston Scientific an estimated $3B loss in market capitalization. Source: BioSpace
Struggling The Medicines Company Deals Its Infectious Disease Biz to Melinta for $270M
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics. Source: BioSpace
Wavelength Pharma Names Former Sun Exec as New CEO
Iftach Seri previously served as Sun Pharmaceutical’s head of API. Source: BioSpace
OIG: Medicare Spent $366 Million More by Including Self-Administered Drugs in Part B Calculations
Medicare and its beneficiaries would face significantly lower costs for drugs if the Centers for Medicare and Medicaid Services excluded noncovered versions of drugs while setting Part B drug payments,…
UK Unveils Plan for Investment in Life Sciences
The UK government announced a long-term strategy for the nation’s industries, including a multi-billion pound initiative to boost investment in the life sciences sector. Source: Drug Industry Daily
EMA Outlines Methods for Transferring Product Approvals Before Brexit
The European Medicines Agency published new, practical guidance for marketing authorization holders in navigating the UK’s 2019 departure from the European Union — including the procedures for classifying any Brexit-related…
Gottlieb Previews Upcoming Guidances on Complex Generics
The FDA is working to develop and finalize a handful of new guidances on bringing complex generics to market — including complicated medicines that may require alternate methods of establishing…
Auris Abandons Hearing-Loss Drug After Phase III Flop, Stock Sinks
AM-111 failed to meet its primary endpoint, although the company is putting a positive spin on it by noting it was effective in a subpopulation. Source: BioSpace
- Go to the previous page
- 1
- …
- 244
- 245
- 246
- 247
- 248
- 249
- 250
- …
- 610
- Go to the next page